JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

Home・Elenco Azioni・Incyte Corp

Search

Incyte Corp

Aperta

SettoreSettore sanitario

96.33 -0.91

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

96.42

Massimo

97.44

Metriche Chiave
By Trading Economics
Entrata	-125M 299M
Vendite	141M 1.5B
P/E Media del settore	14.932 67.147
Margine di Profitto	19.861
Dipendenti	2,844
EBITDA	-92M 415M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+11.51% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-2.4B 19B
Apertura precedente	97.24
Chiusura precedente	96.33

Notizie sul Sentiment di mercato

By Acuity

32%

68%

110 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

59.52 / 62.66 Supporto e resistenza

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 22:17 UTC

Utili

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mag 2026, 23:47 UTC

Utili

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mag 2026, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mag 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 mag 2026, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mag 2026, 22:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mag 2026, 22:26 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mag 2026, 22:02 UTC

Utili

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mag 2026, 22:00 UTC

Discorsi di Mercato

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mag 2026, 21:52 UTC

Utili

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mag 2026, 21:49 UTC

Utili

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mag 2026, 21:43 UTC

Utili

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mag 2026, 21:41 UTC

Utili

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mag 2026, 21:40 UTC

Utili

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

11.51% in crescita

Previsioni per 12 mesi

Media 108.06 USD 11.51%

Alto 135 USD

Basso 75 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

8

Acquista

10

Mantieni

1

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

Bullish events outweigh bearish events.

All events are bearish.

All events are bearish.

Sentiment

By Acuity

110 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Altri titoli del settore

JNJ

Johnson and Johnson

225.54

UNH

UnitedHealth Group Inc

370.35

TMO

Thermo Fisher Scientific Inc

465.79

ISRG

Intuitive Surgical Inc

450.79

ABT

Abbott Laboratories

86.59

Live chat